Clinical trial
Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin
NCT00082407 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin
- Lead sponsor
- AstraZeneca
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2003
- Completion date
- July 31, 2008
- Enrollment
- 505 (actual)
- Sites
- 69
Conditions
As the registry lists them; a condition with its own page is linked.